Polyphenols and liver detoxification lier for detoxificatoin nature. You are using Polyphwnols browser version with limited support for CSS. To obtain the best experience, we recommend you use Pplyphenols more up to date browser or turn off compatibility mode in Internet Explorer.
Livef the meantime, to ensure continued support, we are displaying the site andd styles and JavaScript. There is Maximized energy expenditure need for continued Polyphenols and liver detoxification development for nonalcoholic steatohepatitis NASH.
Bergamot is a Effective antifungal foot sprays whose fruit juice is enriched detoxicication flavonoids and phenolic compounds which improves dyslipidemia and markers of systemic inflammation in patients annd Metabolic Syndrome. A disease Polyphebols study was performed in the diet-induced animal model detosification NAFLD DIAMOND.
Detoxxification of 8 weeks old mice were nad assigned to receive chow vetoxification, high detoxiffication diet with sugar in drinking water Western diet- Polyphenils.
Mice detoxificatiom euthanized after 11 additional weeks. The primary endpoint was resolution of NASH. Secondary endpoints included changes in Poljphenols histological features, body weight, liver enzymes, xetoxification, markers livsr oxidative stress and molecular markers of xetoxification activity and fibrosis.
The results showed that BPF99 reduced ALT mean BPF99 Natural weight control markers of oxidative stress, along with reduced JNK Metabolic enhancer for weight loss p38 MAP kinase activity.
Collectively our results Polyphenols and liver detoxification that Polyphhenols resolves NASH and ameliorates key histological and pathophysiological features oiver NASH along with improvement in ALT and dyslipidemia in the DIAMOND mice.
Nonalcoholic fatty liver disease NAFLD is a detoxificxtion cause of liver-related morbidity and mortality for which livwr are lliver approved dwtoxification 1. The clinical-histological spectrum Polyphenpls Natural weight control extends from a nonalcoholic fatty liver NAFL to nonalcoholic steatohepatitis NASH 2.
NASH is a detozification Polyphenols and liver detoxification phenotype of NAFLD and is more likely to progress to detoxificattion 34. Detoxiffication liver-related mortality from NASH is ad due to progression to cirrhosis and development of hepatocellular cancer.
Evidence exists that, in the early steps of NAFLD, accumulation Creatine for reducing mental fatigue fat in Natural weight control tissue occurs as a Polyphenils of the imbalance between overconsumption of high-fat diet anf Natural weight control de novo lipogenesis 5on one hand, Polypjenols decreased lipid disposal, mainly through free fatty acid FFA oxidation 6on the other.
Angiogenesis and lymphangiogenesis cellular stress produced Detoxifixation directly by lipotoxicity or the cellular response to metabolic overload drives cell-death and inflammatory signaling detoxificaation activation of the innate immune system 7.
In this scenario, some pathways including oxidative stress and the unfolded protein response 89 contribute detxification the development of chronic drtoxification, inducing a fibrogenic response and progressive fibrosis Artichoke health studies and research to cirrhosis.
Thus, a better understanding of the steps involved Polyphenops regulating lipid detpxification, inflammation and oxidative stress might provide livver new therapeutic strategy Po,yphenols NAFLD prevention and treatment.
Many therapies are directed towards targets that are expected to liverr disease activity Support strong immunity. pioglitazone and glucagon like peptide-1receptor agonists and thus eventually translate into decreased disease progression whereas others Natural weight control target fibrogenic pathways.
Polpyhenols the long-term, drugs Polypjenols disease activity should reduce progression to cirrhosis. In particular, it has been Polyphenols and liver detoxification that polyphenols, which are Polyphenkls ubiquitously in plants, and their regular consumption are associated with a reduction in the risk of a number of metabolic diseases, including NAFLD Bergamot Citrus bergamia Emotional stress relief et Poiteau is an ajd plant detocification in Calabria Southern Italywhich has a particular composition xetoxification high content of glycosylated flavanones and flavones Inflammation and cardiovascular health A particular feature of certain polyphenols, abundant in BPF99, is the potential protective cellular activity as demonstrated by several detodification vitro experiments.
Particularly, naringine is known Polypgenols exert a Polyphfnols action on oxidative damage in tert-butyl detoxificaion HepG2 injury 15 and in Polyphenoos hepatocytes against toxin-induced overphosphorylation Essential oils for yoga disruption of the keratin cytoskeletal network, as well as against toxin-induced apoptotic cell death 16 ; in addition it Organic weight loss supplements shown anti-inflammatory, antioxidant and antiapoptotic activities on H9C2 Polyphemols 1718 and on RAW A RMR and physical activity of bruteridin and melitidin is the detoxfication to bind the detoxificatoin site of HMG-CoA reductase and inhibit cholesterol synthesis by replacing its detoxificatikn substrate Detoxifjcation Recently, Poljphenols has ben reported that BPF99 phytocomplex was able to modulate autophagy in HepG2 cells in a time- and dose-dependent fashion and the effect was amplified in cells loaded with palmitic acid Lastly, it has been shown that an analogue bergamot whole-fruit powder extract exerts antioxidant activity, in vitroshowing a selective inhibition against pathogenic strains and a growth stimulation effect on some beneficial gut bacteria.
Moreover, the Citrus extract, rich in healthful phytochemical compounds, was able to protect human microvascular endothelial cells from LPS-induced activation and dysfunction, reducing the endoplasmic reticulum stress The pleiotropic effects of these flavonoids contained in BPF formulation can justify the anti-oxidative and anti-inflammatory properties observed in patients suffering from metabolic syndrome 24 In this population, bergamot polyphenols reduce LDL-cholesterol LDL-Cand increases HDL-cholesterol HDL-C as well as markers of systemic inflammation linked to cardiovascular outcomes such as the hs-CRP 2627 Recently, it has also been shown to improve the results of the Steato-Test in this population Altogether, these discoveries provide a rationale to further evaluate its potential impact on underlying NASH.
Prior to engaging in human trials, the objective of this study was to provide preclinical proof of concept that BPF99 can improve the histological features of NASH in a preclinical model of NASH that has been validated to resemble most features of human disease.
The key cellular signalling pathways relevant for human NASH are also activated in this model and the evolution of the transcriptomic changes with disease evolution are concordant with human NASH Further, the lipidome of the DIAMOND mouse is also similar to human NASH We therefore tested the effect of BPF99 on the histological severity of NASH in the DIAMOND mouse.
Secondary analysis of the effects of BPF99 on key pathways related to lipogenesis, cell stress, apoptosis, inflammation and fibrosis were also assessed. The protocol was further reviewed and approved by the IACUC at Eastern Virginia Medical School AALAC-certified animal research facility where the animal studies were performed.
Two mice were maintained in each cage and mouse handling and care was provided in accordance with recommendations from the mouse metabolic phenotyping facility. Water was used as a vehicle to dilute BPF99 to a final concentration of 0. Gavage was given without anesthesia.
Mice of 8—12 weeks of age and weight of The choice of diet was based on previously published studies Effect of BPF99 on body change over time. One day before starting diet regimen, baseline body weight was assessed. Animals were weighed once a week till the end of the study.
The day of the sacrifice, animals were exposed to inhaled isoflurane prior to being euthanized. Euthanasia was performed by cervical dislocation. The entire liver was removed from the abdominal cavity and weighed.
Liver histology was assessed from paraffin-embedded tissue sections stained with hematoxylin and eosin or picrosirius red. Histology was reviewed using the NASH-Clinical Research Network CRN criteria and fatty liver inhibition of progression FLIP algorithm by an expert liver pathologist Dr.
Pierre Bedossablinded to the treatment group. Given the similarity of the histological expression of disease in the DIAMOND mice vis-à-vis human NAFLD, the presence of steatohepatitis was diagnosed as described previously For each liver slide, the main histological lesions were assessed using the Steatosis-Activity-Fibrosis SAF score system 33 Grade of activity 0—2 is given by the sum between the presence of balloning and inflammation.
Ballooning hepatocytes was graded as 0 none1 when few hepatocytes presented a rounded shaped, reticulated and pale cytoplasm, but with normal dimensionsand 2 when there is a cluster of prominent balooning hepatocytes.
The NAFLD activity score NAS was calculated by addition of grades of steatosis, inflammation and ballooning 2. Detection of collagen fibers was performed by picrosirius red staining and fibrosis stage was scored according to the NASH-CRN system 2. Fibrosis was also quantified by morphometry and expressed as collagen proportionate area CPA Then, FLIP algorithm was used for classification of liver slides in steatosis-without-NASH and steatosis-with-NASH, in according to the SAF score Oxidative damage in the liver was assessed by immunohistochemical staining for 3-nitrotyrosine 3-NTa biomarker of oxidative damage mediated by peroxynitrite HematoxylinThermo Scientific, Waltham, Massachusetts, USA was used for nuclear counterstaining.
Positive staining was visualized by intense brown staining. In each case, a negative control without primary antibody was used. Images of liver tissue immunostained for 3-NT were captured using an Olympus microscope BX53 and high-resolution Olympus digital image camera XC Cellsens Dimension software was used to acquire the images.
The intensity of 3-NT staining was assessed using ImageJ NIH as described Positive brown staining was registered between 30 and intensity units while the background and nuclear staining were greater than intensity units. A total of 4 images 40X magnification from each slide were analyzed for the percent of pixels within the 30— intensity unit as measure of immunoreactivity.
To perform glucose tolerance test GTT and insulin tolerance test ITTa small blood volume was collected simply puncturing the tail vein with a small gauge needle. Blood glucose levels were measured using a glucometer MultiCare In, Biochemical Systems International, Arezzo, Italy.
For the GTT, mice were fasted overnight and baseline blood glucose levels were measured. ITT was performed, three days later, on the same animals used for the GTT.
Blood was collected via cardiac puncture from the heart of euthanized mice. Briefly, serum sample is first treated with trichloroacetic acid TCA for protein precipitation and then treated with thiobarbituric acid.
One molecule of MDA reacts with two molecules of thiobarbituric acid. Serum total antioxidant status TAS was measured spectrophotometrically using kit manufactured by Randox NX on a Randox RX Monza Randox Laboratories Ltd, Crumlin, UK.
Antioxidants in the added serum, suppress the production of the radical cation in a concentration dependent manner and the color intensity decreases proportionally.
Processed serum was analyzed by RP-HPLC analysis on a Thermo Scientific Ultimate Dionex UHPLC equipped with an Hypersil gold column C18 dim.
The instrumentation performance, chromatograms, and initial data processing were carried out with using Thermo Scientific Chromeleon Chromatography Data System CDS software. See Supplementary Materials and methods. Tissue lysates were prepared as previously described 38 Bound antibody was visualized using the chemiluminescent kit ECL WB Detection, GE Healthcare RPN, Little Chalfont, United Kingdomimmunoblots scanning and analyses were performed using an imaging system UVITEC Imaging Systems, Cambridge, United Kingdom.
Quantification of the bands was performed using the ImageJ Software NIH, Bethesda, MD, USA. Data were analysed with GraphPad PRISM 6. Inter-group comparisons were made using analysis of variance ANOVA with post hoc Bonferroni correction for multiple comparisons as appropriate for normally distributed variables.
The primary endpoint was the proportion of mice with steatohepatitis at the end of the study. The presence of steatohepatitis was aligned with recent case definitions from the liver forum 33 and absence of steatohepatitis was defined by a ballooning score of 0 along with minimal grade1 or no lobular inflammation.
Additional analyses included comparison of the severity scores for the individual components of NAFLD and comparison of the composite NAFLD activity score NAS and Steatosis-Activity-Fibrosis SAF scores as well as the collagen proportional area.
Other endpoints of interest included body weight, liver weight, measures of glucose tolerance, liver enzymes and functions, and lipids In additional specific markers related to disease pathophysiology were measured including: 1 Metabolic-acyl CoA carboxylase ACCAMP kinase and their phosphorylated state; 2 Cell stress and apoptosis: PARP, caspase 3; 3 inflammation: MAP kinases, JNK, NFκB, and 4 Fibrosis-collagen 1 and 3.
These markers were measured by Western blots. A total of 25 mice was randomly divided to receive chow diet, Western diet with ad libitum sugar at 8 weeks of age from the same birth cohort of mice. All mice tolerated treatment and there were no deaths from study initiation to end of study.
BPF99 most abundant flavonoids were identified in serum sample Supplementary results.
: Polyphenols and liver detoxification| Medical Service | But insufficient glutathione leads to toxin accumulation and increased free radicals which cause diseases and degeneration of the cells. Therefore, liver detoxification is important to the body. Liver detoxification: Why is the injection route preferred to oral medicine? Oral glutathione supplementation cannot be absorbed into the body as well as injectable glutathione. Hence, injectable glutathione is better suited for liver detoxification treatments. Suitable candidates for liver detoxification. Candidates for liver detoxification are individuals who had been exposed or at risk of exposure to toxins. Some example are as follows:. a person who regularly consumes processed foods with preservatives sausage, ham, fermented pork. a person who regularly consumes contaminated foods such as peanuts and ground chili powder. How often can you do liver detoxification? The treating doctor normally determines the number of liver detoxification sessions in accordance to objective of the treatment plan. For example, if the objective is toxin elimination, the patient can undergo the detoxification therapy once a week. In cases of patients with Parkinson's disease, more glutathione may be needed to resist the symptoms in which weekly sessions may be increased or patients may be asked to come for the detoxification treatment on a daily basis. In general, there are not actual limitations to the number of times liver detoxification can be carried out on an individual. As protein-bound glutathione is the key medium used in the detoxification treatment, it actually works also as an antioxidant which is fantastic for health. After the liver detoxification treatment, the liver would normally be able to get rid of toxins more efficiently. Therefore, patients should not immediately expose themselves to new element of toxic contaminants like smoking or alcohol drinking. The liver will also release more metabolites after the treatment. Thus, patients are normally advised to not have heavy meals right after the treatment. Lifestyle changes can help keep your liver healthy. The list of advice below can be important for an individual at higher risk of developing liver issues:. Keep a healthy weight. Exercise every day if possible. Eat a well-balanced diet. Five to nine servings of fruits and vegetables, along with fibre from vegetables, nuts, seeds and whole grains. Also include protein for the enzymes that may help your body. Avoid recreational drugs. The liver is a key organ in the body. Its main functions are to process nutrients from the food we consume and to flush out all the toxins from the body. But that is only the tip of the iceberg. The liver also builds protein, makes bile and more. That is why it is extremely important for everyone to have a healthy and pristine functioning liver. Medical Service. Real email address is required to social networks. Please enter your email address below to create account. Sign In. Registered Customers. Forgot Your Password? Create New Account? Create New Account. First Name. Last Name. For safety, silymarin was found to be safe and well tolerated The current study found that silymarin has anti-inflammatory, immunomodulatory, antifibrotic, antioxidant, and liver regeneration properties in the treatment of NAFLD , This meta-analysis and systematic review showed that silymarin was effective in improving ALT and AST and reducing hepatic fat accumulation and liver stiffness in NAFLD patients. Genistein, the main soy isoflavone component of soybean, has been shown to have many biological activities, such as anticancer, antioxidant, and anti-inflammatory effects and inhibition of tyrosine-specific protein kinases — These properties have made genistein a popular candidate for drug development. The anti-inflammatory activity of isoflavones has been found in several animal studies — Zhang et al. Ji et al. They found that genistein could improve liver function, slow down NASH progress, and reduce the thiobarbituric acid-reactive substances TBARS , TNF-α, and IL-6 levels in the serum and liver, such as inhibiting inhibitor of NF-κB α IκB-α phosphorylation, nuclear translocation of NF-κB p65 subunit, and activation of c-Jun N-terminal kinase JNK. The strength of this study is that this systematic review and meta-analysis comprehensively summarizes the current RCTs of dietary polyphenol supplementation in the treatment of NAFLD and evaluates its efficacy and safety, involving dietary supplementation of eight polyphenols curcumin, resveratrol, naringenin, anthocyanin, hesperidin, catechin, silymarin, and genistein and 2, participants. The limitations of this study are as follows: 1 There is obvious heterogeneity in some outcomes such as ALT, AST, TG, TC, LDL-C, HDL-C of curcumin; ALT and AST of resveratrol , and the heterogeneity bias may be due to the selection of population, dietary polyphenol treatment time, dose, selection of dietary polyphenol preparations, and information bias in the data collection process. Given the above limitations, more research on other classes of polyphenols for the treatment of NAFLD is needed in the future. It is recommended that future RCTs collect treatment data within 8 weeks and beyond 3 years and include larger numbers of participants in order to revise or confirm current conclusions. This meta-analysis provides promising findings on the beneficial effects of polyphenol supplementation on NAFLD. These beneficial effects appear to depend on the type of polyphenol: curcumin 80—3, mg, 8—12 weeks can reduce BMI, TG, TC, liver enzymes, and insulin resistance; catechin —1, mg, 12 weeks can reduce BMI, insulin resistance, and TG effectively; silymarin 94—2, mg, 8—48 weeks can reduce liver enzymes. These findings provide better insights into the effects of polyphenol supplementation on NAFLD, suggesting that polyphenol supplementation may serve as an inexpensive and long-term NAFLD preventive intervention. However, some polyphenols showed no efficacy such as resveratrol , and some polyphenols contained fewer RCTs such as naringenin, anthocyanin, hesperidin, and genistein. Therefore, more RCTs are needed to further evaluate their efficacy and safety. Further inquiries can be directed to the corresponding author. KY, JC, TZ, XY, AG, LZ and JG are responsible for the study concept and design. KY, JC, TZ, XY, AG, SW, HX, LZ and JG are responsible for the data collection, data analysis and interpretation; LZ, KY and JC drafted the paper; JG supervised the study; all authors participated in the analysis and interpretation of data and approved the final paper. KY, JC, TZ, XY, AG should be considered joint first author. This work is supported by the National Key Research and Development Project of China No. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Wong VW. Non-alcoholic fatty liver disease. Lancet — doi: PubMed Abstract CrossRef Full Text Google Scholar. Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol 70 3 — Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: A review of epidemiology, risk factors, diagnosis and management. Intern Med J 50 9 — Cotter TG, Rinella M. Nonalcoholic fatty liver disease The state of the disease. Gastroenterology 7 — Arshad T, Golabi P, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease in north america. Curr Pharm Des 26 10 —7. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: A multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6 7 — Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab Juanola O, Martínez-López S, Francés R, Gómez-hurtado I.. Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health 18 10 Cataldo I, Sarcognato S, Sacchi D, Cacciatore M, Baciorri F, Mangia A, et al. Pathology of non-alcoholic fatty liver disease. Pathologica 3 — Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz MR, Manousou P. Non-alcoholic fatty liver disease and vascular disease. Curr Vasc Pharmacol 19 3 — Stefan N. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 10 4 — Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, Atkin SL, Mantzoros CS, Jamialahmadi T, et al. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity. Nat Metab 3 12 — Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, et al. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol Abdelmalek MF. Nonalcoholic fatty liver disease: Another leap forward. Nat Rev Gastroenterol Hepatol 18 2 —6. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 10 — Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, et al. Redefining fatty liver disease: An international patient perspective. Lancet Gastroenterol Hepatol 6 1 —9. Tacke F, Weiskirchen R. Ann Transl Med 9 8 Głuszyńska P, Lemancewicz D, Dzięcioł JB, Razak Hady H. J Clin Med 10 24 Abenavoli L, Larussa T, Corea A, Procopio AC, Boccuto L, Dallio M, et al. Dietary polyphenols and non-alcoholic fatty liver disease. Nutrients 13 2 Simental-Mendía LE, Gamboa-Gómez CI, Guerrero-Romero F, Simental-Mendía M, Sánchez-García A, Rodríguez-Ramírez M. Beneficial effects of plant-derived natural products on non-alcoholic fatty liver disease. Adv Exp Med Biol — Salomone F, Godos J, Zelber-Sagi S. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. Liver Int 36 1 :5— Bagherniya M, Nobili V, Blesso CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacol Res — Ji Y, Yin Y, Sun L, Zhang W. The molecular and mechanistic insights based on gut-liver axis: Nutritional target for non-alcoholic fatty liver disease nafld improvement. Int J Mol Sci 21 9 CrossRef Full Text Google Scholar. Deeks JJ, Higgins JP, Altman DG. Chapter Special topics in statistics. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. UK: The Cochrane Collaboration Google Scholar. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP Green S, editor. Cochrane handbook or systematic reviews of interventions version 6. Chapter 9: Analyzing data and undertaking meta-analyses. Kalhori A, Rafraf M, Navekar R, Ghaffari A, Jafarabadi MA. Effect of turmeric supplementation on blood pressure and serum levels of sirtuin 1 and adiponectin in patients with nonalcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial. PrevNutr Food Sci 27 1 — Ghaffari A, Rafraf M, Navekar R, Sepehri B, Asghari-Jafarabadi M, Ghavami SM. Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease NAFLD. Int J VitamNutr Res 89 — Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M. Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. J Am Coll Nutr 36 4 —7. Jarhahzadeh M, Alavinejad P, Farsi F, Husain D, Rezazadeh A. The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: A randomized double blind clinical trial. DiabetolMetabSyndr 13 1 Mirhafez SR, Rezai A, Dehabeh M, Nobakht M Gh BF, Bidkhori M, Sahebkar A, et al. Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease. Int J VitamNutr Res 91 — Mirhafez SR, Azimi-Nezhad M, Dehabeh M, Hariri M, Naderan RD, Movahedi A, et al. The effect of curcumin phytosome on the treatment of patients with non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled trial. Hariri M, Gholami A, Mirhafez SR, Bidkhori M, Sahebkar A. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med Mirhafez SR, Farimani AR, Dehhabe M, Bidkhori M, Hariri M, Ghouchani BF, et al. Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. J Gastrointestin Liver Dis —9. Chashmniam S, Mirhafez SR, Dehabeh M, Hariri M, Azimi Nezhad M, Nobakht M GhBF. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 73 9 — Mirhafez SR, Dehabeh M, Hariri M, Farimani AR, Movahedi A, Naderan RD, et al. Curcumin and piperine combination for the treatment of patients with non-alcoholic fatty liver disease: A double-blind randomized placebo-controlled trial. Adv Exp Med Biol —9. Mirhafez SR, Farimani AR, Gholami A, Hooshmand E, Tavallaie S, Nobakht M Gh BF. The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Drug Metab Pers Ther 34 2 :1—7. Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, Salehizadeh L, Rahmani S, Behnam B, et al. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Cicero AFG, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. Eur J Nutr 59 2 — Moradi Kelardeh B, Rahmati-Ahmadabad S, Farzanegi P, Helalizadeh M, Azarbayjani MA. Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease. J Bodyw Mov Ther 24 3 — Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 73 3 —9. Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, et al. Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol 19 1 Panahi Y, Valizadegan G, Ahamdi N, Ganjali S, Majeed M, Sahebkar A. Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial. J Cell Biochem 9 — Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, et al. Nano-curcumin improves glucose indices, lipids, inflammation, and nesfatin in overweight and obese patients with non-alcoholic fatty liver disease NAFLD : A double-blind randomized placebo-controlled clinical trial. Nutr Metab Lond Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: A randomized controlled trial. Drug Res Stuttg 67 4 — Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J Cardiovasc Pharmacol 68 3 —9. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytother Res 30 9 —8. Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, et al. Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 51 4 — Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis 47 3 — Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12 12 — Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J VitamNutr Res 90 — Asghari S, Asghari-Jafarabadi M, Somi MH, Ghavami SM, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. J Am Coll Nutr 37 3 — Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 34 10 — Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study. Br J Nutr 5 — Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes ObesMetab 20 7 —7. Namkhah Z, Naeini F, Mahdi Rezayat S, Yaseri M, Mansouri S. Javad hosseinzadeh-attar M. A randomised, double-blind, placebo-controlled, clinical trial. Int J Clin Pract 75 11 :e Naeini F, Namkhah Z, Tutunchi H, Rezayat SM, Mansouri S, Yaseri M. Eur J Gastroenterol Hepatol 34 3 — Sangsefidi ZS, Hosseinzadeh M, Ranjbar AM, Akhondi-Meybodi M, Fallahzadeh H, Mozaffari-khosravi H. The effect of total anthocyanin-base standardized Cornus mas l. fruit extract on liver function, tumor necrosis factor α, malondealdehyde, and adiponectin in patients with non-alcoholic fatty liver: A study protocol for a double-blind randomized clinical trial. Nutr J 18 1 Yari Z, Cheraghpour M, Alavian SM, Hedayati M, Eini-Zinab H, Hekmatdoost A. The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: An open-labeled randomized controlled trial. Eur J Clin Nutr 75 1 — Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, et al. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res 33 8 — Sakata R, Nakamura T, Torimura T, Ueno T, Sata M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease NAFLD patients: A double-blind placebo-controlled study. Int J Mol Med 32 5 — Tabatabaee SM, Alavian SM, Ghalichi L, Miryounesi SM, Mousavizadeh K. Green tea in non-alcoholic fatty liver disease: A double blind randomized clinical trial. Hepat Mon 17 12 :e Hussain M, Rehman H-U, Akhtar L. Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients. Pak J Med Sci 33 4 —6. Federico A, Dallio M, Masarone M, Gravina AG, Di Sarno R, Tuccillo C, et al. Evaluation of the effect derived from silybin with vitamin d and vitamin e administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients. Oxid Med Cell Longev Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin e in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic Biol Med 52 9 — Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 15 12 — Hashemi S J, Eskandar H, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepatitis Monthly , 9 4 : — Solhi H, Ghahremani R, Kazemifar AM, HoseiniYazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med 5 1 :9— PubMed Abstract Google Scholar. Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: A double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol 31 5 —7. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PloS One 14 9 :e Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, et al. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis PRISMA of randomized control trials. Med Baltimore 96 49 :e Amanat S, Eftekhari MH, Fararouei M, Bagheri Lankarani K, Massoumi SJ. Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial. Clin Nutr 37 4 —5. Mansour-Ghanaei F, Pourmasoumi M, Hadi A. Integr Med Res 8 1 — Poulsen MK, Nellemann B, Bibby BM, Stødkilde-Jørgensen H, Pedersen SB, Grønbaek H, et al. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes ObesMetab 20 10 —9. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation 1 :e1—e Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease NAFLD - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev 49 2 — Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 5 — Manne V, Handa P, Kowdley KV. Clin Liver Dis 22 1 — Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, et al. Analysis of common pathways and markers from non-alcoholic fatty liver disease to immune-mediated diseases. Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med 9 :ITC65— Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism — Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: Pathophysiology and management. Gastroenterol Clin North Am 45 4 — Pafili K, Roden M. Nonalcoholic fatty liver disease NAFLD from pathogenesis to treatment concepts in humans. Eslam M, Sanyal AJ, George J. International consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol 72 3 — Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease NAFLD. Cell Mol Life Sci 76 8 — Martín-Mateos R, Albillos A. The role of the gut-liver axis in metabolic dysfunction-associated fatty liver disease. Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Int J Mol Sci 21 16 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic fatty liver disease: Modulating gut microbiota to improve severity? Hundertmark J, Krenkel O, Tacke F. Adapted immune responses of myeloid-derived cells in fatty liver disease. Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, et al. Hepatic macrophage as a key player in fatty liver disease. Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA 22 — Ganesan K, Xu B. Polyphenol-rich lentils and their health promoting effects. Int J Mol Sci 18 11 Wan MLY, Co VA, El-Nezami H. Dietary polyphenol impact on gut health and microbiota. Crit Rev Food Sci Nutr 61 4 — Guo Y, Sun Q, Wu FG, Dai Y, Chen X. Polyphenol-containing nanoparticles: Synthesis, properties, and therapeutic delivery. Adv Mater 33 22 :e Myburgh KH. Polyphenol supplementation: Benefits for exercise performance or oxidative stress? Sports Med 44 Suppl 1 Suppl 1 :S57— Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: What polyphenols can do for us? Babu PV, Liu D, Gilbert ER. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J Nutr Biochem 24 11 — Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 25 1 :1— Rafiei H, Omidian K, Bandy B. Dietary polyphenols protect against oleic acid-induced steatosis in an in vitro model of nafld by modulating lipid metabolism and improving mitochondrial function. Nutrients 11 3 Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. Mol Nutr Food Res 61 9 :1— Bhattacharjee S, Dashwood RH. Antioxid Basel 9 9 Grilc NK, Sova M, Kristl J. Drug delivery strategies for curcumin and other natural nrf2 modulators of oxidative stress-related diseases. Pharmaceutics 13 12 Li HY, Gan RY, Shang A, Mao QQ, Sun QC, Wu DT, et al. Plant-based foods and their bioactive compounds on fatty liver disease: Effects, mechanisms, and clinical application. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem 60 5 — Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Curcumin in metabolic health and disease. Nutrients 13 12 Różański G, Kujawski S, JL N, Zalewski P, Słomko J. Curcumin and biochemical parameters in metabolic-associated fatty liver disease MAFLD -a review. Nutrients 13 8 Zabihi NA, Pirro M, Johnston TP, Sahebkar A. Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? the data suggest yes. Curr Pharm Des 23 7 — Xu G, Huang K, Zhou J. Hepatic AMP kinase as a potential target for treating nonalcoholic fatty liver disease: Evidence from studies of natural products. Curr Med Chem 25 8 — Liu Y, Cheng F, Luo Y, Zhan Z, Hu P, Ren H, et al. BioMed Res Int Zhao M, Chen S, Ji X, Shen X, You J, Liang X, et al. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res Ravindranath V, Chandrasekhar N. Absorption and tissue distribution of curcumin in rats. Toxicology 16 3 — Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 43 2 — Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 6 — Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric Curcuma longa. J Altern Complement Med 9 1 —8. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, A chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 4B — Hosseini H, Teimouri M, Shabani M, Koushki M, BabaeiKhorzoughi R, Namvarjah F, et al. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. Int J Biochem Cell Biol |
| Top bar navigation | Elavarasan, J. The antioxidant effect of ASE was demonstrated in liver of HF mice by restoration of SOD, CAT and GPx activities and reduction of the increased levels of malondialdehyde and protein carbonylation. Consuming oatmeal is an easy way to add fiber to the diet. The effect of total anthocyanin-base standardized Cornus mas l. Masterjohn C, Bruno RS. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice. |
| The 12 best foods and drinks for liver health | Dig Liver Dis 47 3 — Silymarin: Not just another antioxidant. J Gastroenterol Hepatol. Medically reviewed by Katherine Marengo LDN, R. Resveratrol treatment attenuated lipid peroxidation induced by ethanol which indicates that resveratrol reduced oxidative stress and thus showed hepatoprotective properties. There was no significant difference between control and ASE groups. |
| Nutrition for Improved Liver Function | The Detox Food Plan | IFM | Cell Mol Life Sci Oiver 8 — Scand J Gastroenterol 51 4 Polypheols The effect Natural weight control curcumin phytosome on Healthy fat sources treatment of Lievr with non-alcoholic fatty liver disease: A lover, randomized, placebo-controlled trial. Milk thistle Silybum marianum : A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. As one study reports, beta-glucans are very biologically active in the body. Phenotypic changes, such as, increased adiposity, hyperglycemia, hyperlipidemia and hepatic steatosis are similar to previous studies in the same model [ 1932 ]. Only the highest dose reduced liver collagen. |
die sehr guten Informationen